---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000842"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:42:07.497693+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP

## Summary
- Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
- OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).
- No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.
- Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025.

## SEC filing metadata
- accession: 0001753926-25-000842
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/0001753926-25-000842-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/g084819_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000842
- JSON: https://secwatch.observer/filing/0001753926-25-000842.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000842.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.